Clinical ResearchAntithrombic TherapyPerformance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation: The AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study
Antithrombic Therapy
Under an Elsevier user license
open archive
Key Words
AMADEUS trial
ATRIA
atrial fibrillation
bleeding
HAS-BLED
HEMORR2HAGES
Abbreviations and Acronyms
AF
atrial fibrillation
ATRIA
Anticoagulation and Risk Factors in Atrial Fibrillation
DCA
decision-curve analysis
HAS-BLED
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol
HEMORR2HAGES
Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke
ROC
receiver-operating characteristic
Cited by (0)
The AMADEUS study was funded by the Sanofi-Aventis Group.
Dr. Lane has received research funding and/or honoraria for educational symposia from Boehringer-Ingelheim, Bayer Healthcare, and Bristol-Myers Squibb/Pfizer in relation to atrial fibrillation. Prof. Buller has served as a consultant to the Sanofi-Aventis Group, Bayer, Pfizer, GlaxoSmithKline, Astellas, Boehringer-Ingelheim, and Daiichi-Sankyo. Prof. Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, the Sanofi-Aventis Group, BMS/Pfizer, Portola, Biotronic, and Boehringer-Ingelheim; and has been on the speakers' bureaus for Bayer, Boehringer-Ingelheim, BMS/Pfizer, and the Sanofi-Aventis Group.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.